

JOHN STEPHEN BRIDGEMAN

Home Address: 87 Mallard Crescent, Poynton, Cheshire, SK12 1XG

Work Address: Cellular Therapeutics Ltd. UMIC Bio-Incubator, 48 Grafton Street, Manchester, M13 9XX

Email Address – j.bridgeman@cellulartherapeutics.co.uk

Tel. N°. – 0161 603 7732

Date of Birth – 10 December 1979

Nationality – British

Employment

2014 – Present

Director of Cell Therapy Research: Cellular Therapeutics Ltd. Manchester

Honorary Lecturer: Institute of Cancer Sciences, University of Manchester

Honorary Senior Research Fellow: Institute of Infection & Immunity, Cardiff University

2013 – 2014

Wellcome Trust/NISCHR Research Fellow: Institute of Infection & Immunity, Cardiff University

2010 – 2013

Post-Doctoral Research Associate: Institute of Infection & Immunity, Cardiff University

2009 – 2010

Post-Doctoral Research Associate: Childrens' Cancer Group, University of Manchester

2008 – 2009

Post-Doctoral Research Associate: Cellular Therapy Group, University of Manchester

Education

2004 – 2008 PhD University of Manchester, Supervisors: Dr. David Gilham & Prof. Robert Hawkins

2002 – 2003 MSc (Dist.) – Molecular Parasitology & Vector Biology: Universities of Salford, Manchester & Keele

1999 – 2002 BSc (Hons) 1st, Biological Sciences: University of Salford

Grants, Awards and Memberships

BSGCT/Nuffield Foundation Studentship (Supervisor) – 2012 & 2013

Wellcome Trust/NISCHR Seedcorn grant (Co-applicant) – 2012

Membership and awareness sub-committee British Society for Gene and Cell Therapy – 2013

Wellcome Trust/NISCHR Fellowship – 2013

Poster award: Adoptive immune cell therapy symposium – 2014

Communications and promotion sub-committee British Society for Gene and Cell Therapy – 2014

Oral Presentations

PEGS Boston – 2016 (Invited talk)

Adoptive T-cell Therapy Congress – 2016 (Invited talk)

Miltenyi T-cell symposium – 2015 (Invited talk)

British Society of Immunology conference – 2013

British Society for Gene Therapy conference – 2007

Public Engagement

Science in Health Work Experience Scheme – 2012 & 2013

Researcher in Residence Award – 2011

Student supervision

PhD (Co-supervisor - Three student) MRes (Four students), BSc (Two students), BSGCT/Nuffield Foundation Studentship (Two students)

Publications

Dockree, T; Holland, C.J; Clement, M; Ladell, K; McLaren, J.E; van den Berg, H.A; Gostick, E; Miners, K.L; Llewellyn-Lacey, S; Bridgeman, J.S; Man, S; Bailey, M; Burrows, S.R; Price, D.A; Wooldridge, L. – CD8⁺ T-cell specificity is compromised at a defined MHC/CD8 affinity threshold. *Immunol Cell Biol.* 2016 Nov 8. Epub ahead of print

Pageon, S.V; Tabarin, T; Yamamoto, Y; Ma, Y; **Bridgeman, J.S**; Cohnen, A; Benzing, C; Gao, Y; Crowther, M.C; Tungatt, T; Dolton, G; Sewell, A.K; Price, D.A; Acuto, O; Parton, R.G; Gooding, J.J; Rossy, J; Rossjohn, J; Gaus, K. – Functional role of T-cell receptor nanoclusters in signal initiation and antigen discrimination – *PNAS* ePub ahead of print Aug 29 2016

Gilham, D.E; Anderson, J; **Bridgeman, J.S**; Hawkins, R.E; Exley, M.A; Stauss, H; Maher, J; Pule, M; Sewell, A.K; Bendle, G; Lee, S; Qasim, W; Thrasher, A; Morris, E. - Adoptive T-cell therapy for cancer in the United Kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. *Hum Gene Ther.* 2015 May;26(5):276-85.

Motozono, C; **Bridgeman, J.S**; Price, D.A; Sewell, A.K; Ueno, T. – Clonotypically similar hybrid $\alpha\beta$ TCRs can exhibit markedly different surface expression, antigen specificity and cross-reactivity – *Clin. Exp. Immunol.* 2015 Jun;180(3):560-70.

Tan, M.P; Gerry, A; Brewer, J; Melchiori, L; **Bridgeman, J.S**; Bennet, A; Pumphrey, N; Jakobsen, B; Price, D.A; Ladell, K; Sewell, A.K. - TCR binding affinity governs the functional profile of cancer-specific CD8⁺ T cells – *Clin. Exp. Immunol.* Dec 15 2014

Cheadle, E.J; Sheard, V; Rothwell, D.G; **Bridgeman, J.S**; Ashton, G; Hanson, V; Mansoor, A.W; Hawkins, R.E; Gilham, D.E. - Differential role of Th1 and Th2 cytokines in auto-toxicity driven by CD19-specific second generation CAR T-cells in a mouse model – *J. Immunol.* 2014, 192(8):3654-65

O'Connor, J.M; Vivian, J.P; Widjaja, J.M; **Bridgeman, J.S**; Gostick, E; Lafont, B.A.P; Anderson, S.K; Price, D.A; Brooks, A.G; Rossjohn, J; McVicar, D.W. - Analysis of KIR3DL1 mutants and allotypic variants uncovers a lineage-defining dimorphism in KIR3DL1 allotypes that impacts both HLA and peptide sensitivity – *J. Immunol.* 2014, 192(6):2875-84

Bridgeman, J.S; Ladell, K; Sheard, V.E; Miners, K; Hawkins, R.E; Price, D.A; Gilham, D.E. - CD3 ζ -based chimeric antigen receptors mediate T-cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy – *Clin. Exp. Immunol.* 2014, 175(2):258-67.

Van den Berg, H.A; Ladell, K; Miners, K; Laugel, B; Llewellyn-Lacey, S; Clement, M; Cole, D.K; Gostick, E; Wooldridge, L; Sewell, A.K; **Bridgeman, J.S**; Price, D.A. Cellular-level versus receptor-level response threshold hierarchies in T-cell activation – *Front. Immunol.* 2013, 4:250.

Ladell, K; Hashimoto, M; Candela Iglesias, M; Wilmann, P.G; McLaren, J.E; Gras, S; Chikata, T ; Kuse, N ; Fastenackels, S; Gostick, E; **Bridgeman, J.S**; Venturi, V; Arkoub, Z.A; Agut, H; van Bockel, D.J ; Almeida, J.R; Douek, D.C; Venet, A; Takiguchi, M; Rossjohn, J; Price, D.A and Appay, V - A molecular basis for the control of pre-immune escape variants by HIV-specific CD8⁺ T-cells – *Immunity*, 2013, 21;38(3):425-36

Bridgeman, J.S; Sewell, A.K; Miles, J.J; Price, D.A; Cole, D.K – Structural and biophysical determinants of $\alpha\beta$ T-cell antigen recognition – *Immunology*, 2012, 135(1): 9-18

Cheadle, E.J; Rothwell, D.G; **Bridgeman, J.S**; Sheard, V.E; Hawkins, R.E; Gilham, D.E – Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T-cells – *Gene Ther.*, 2012, 19(11): 1114-20

Holland, M; Castro, F.V; Alexander, S; Smith, D; Liu, J; Walker, M; Bitton, D; Mulryan, K; Ashton, G; Blaylock, M; Bagley, S; Connolly, Y; **Bridgeman, J**; Miller, C; Krishnan, S; Dempsey, C; Masurekar, A; Stern, P; Whetton, A; Saha, V – RAC2, AEP and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia – *Blood*, 2011, 118(3): 638-49.

Bridgeman, J.S; Hawkins, R.E; Bagley, S; Blaylock, M; Gilham, D.E. - The optimal antigen-response of chimeric antigen receptors harboring the CD3 ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous T cell receptor/CD3 complex. – *J. Immunol.* 2010, 184(12): 6938-49

Rothwell, D.G; Crossley, R; **Bridgeman, J.S**; Sheard, V; Zhang, Y; Sharp, T.V; Hawkins, R.E; Gilham, D.E; McKay, T.R. - Functional expression of secreted proteins from a FMDV 2A bicistronic retroviral cassette can be position-dependent – *Hum. Gene Ther.*, 2010, 21(11): 1631-7.

Bridgeman, J.S; Hawkins, R.E; Hombach, A.A; Abken H; Gilham, D.E. – Building better chimeric antigen receptors for adoptive T-cell therapy, *Curr. Gene Ther.* 2010, 10(2): 77-90

Bridgeman, J.S; Blaylock, M; Hawkins, R.E; Gilham, D.E. - Development of a Flow Cytometric Co-Immunoprecipitation (FCIP) technique for the study of multiple protein-protein interactions and its application to T-Cell Receptor analysis -*Cytometry A.* 2010, 77(4): 338-46

Bridgeman, J.S; Gilham, D.E; Hawkins, R.E; Cheadle, E.J. - The 2nd cellular therapy of cancer symposium, March 27th-29th 2009, Milan, Italy – *Cancer Immunol. Immunother.*, 2010, 59(6): 971-4

Book Chapters

Bridgeman, J.S; Gilham, D.E. – Chimeric antigen receptor gene therapy in cancer. Tumour immunology and immunotherapy: Editor Rees, R.

Bridgeman, J.S; Hombach, A; Gilham, D.E; Eshhar, Z; Abken, H. - T-bodies: Antibody based engineered T-cell receptors. Cellular Therapy of Cancer: Development of Gene Therapy Based Approaches: Editor Hawkins, R.E.

Other

